Sector Update: Healthcare Shares Mixed Pre-Market; Astex Soars 10% on Topline Results from Study of SGI-110

By
A A A

Top Healthcare Stocks:

JNJ: +0.12%

PFE: -0.16%

ABT: +1.44%

MRK: flat

AMGN: +1.71%

Healthcare shares are mixed in pre-market trade. Astex Pharmaceuticals ( ASTX ) is up 9.9% at $6.02 as it reports topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course.

The primary endpoint is overall remission rate. There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate of 17/67 or 25%.

And, EDAP ( EDAP ) says Q2 sales were EUR 4.5 million, or USD 5.9 million, below the Thomson Reuters estimate for USD 7.8 million.

Loss was EUR 0.01 per diluted share, with items. Estimates, usually less items, were for USD $0.05 loss. EDAP shares are down 2% at $2.56 in pre-market trade.

Finally, Sincere Pharmaceutical Group ( SCR ) said its parent company Sincere Holding Limited will buy its shares for $4.83 per ordinary share and $9.66 per American depository share. SCR shares are flat at $9.36 pre-market.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: ASTX , EDAP , SCR

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

WSJ’s House of the Week
WSJ’s House of the Week             

Stocks

Referenced

100%

Most Active by Volume

58,707,995
  • $25.98 ▼ 1.81%
55,057,148
  • $15.52 ▲ 0.19%
48,580,535
  • $69.40 ▲ 1.43%
48,253,528
  • $28.33 ▲ 5.00%
37,923,248
  • $93.939 ▼ 0.52%
37,174,627
  • $44.835 ▲ 0.32%
32,656,684
  • $3.78 ▼ 1.31%
31,770,654
  • $34.06 ▲ 1.07%
As of 7/21/2014, 04:08 PM